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Abstract 
Pannexin 1 (PANX1) is a glycoprotein capable of forming large-pore single-
membrane channels permeable to signaling molecules such as ATP. In this study, we 
interrogated different domains by introducing naturally occurring variants reported in 
melanoma and assessed their impact on the channel function of PANX1 at the cell surface. 
From this, we discovered a novel tyrosine phosphorylation site at Tyr150, that when 
disrupted via a missense mutation resulted in hypo-glycosylation and a greater capacity to 
traffic to the cell-surface and enhanced dye uptake. We have also uncovered a highly 
conserved ancestral allele, Gln5His, that has a greater allele frequency than the derived 
allele Gln5 in global and cancer cohorts but was not associated with cancer aggressiveness. 
Furthermore, Gln5His also did not impact glycosylation, cell-surface localization and 
channel-function in cancer cells. Our findings demonstrate the utility of studying naturally 
occurring variants in understanding diverse mechanisms that regulate PANX1 channel 
function.   
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Chapter 1 
1 Introduction  
1.1 General Overview of the Pannexin Family 
The discovery of the pannexin family, led by Panchin and his colleagues, was first driven 
to uncover proteins homologous to the invertebrate gap junction family (innexins), in 
vertebrate taxonomic groups (1). Using degenerate primers, the pannexin pioneers 
uncovered innexin homologues encoding for PANX1 and PANX2 (1). As a result of their 
presence in many animal phyla, the novel family was named pannexins, derived from the 
Latin words Pan- for “all” and nexus for “connection”, as they were initially thought to 
form gap junctions. Subsequently, the group uncovered and characterized the full human 
sequences for all three members of the pannexin family, pannexin 1, 2, and 3 (PANX1, 
PANX2, PANX3 for humans, and Panx1, Panx2, Panx3 for rodents) (2).  
The evolutionary rise of the pannexin family is predicted to have occurred during two major 
genomic duplications early in the divergence of vertebrates (3), of which the former event 
led to the onset of PANX2 while the latter led to both PANX1 and PANX3 (4). The 
temporal onset of the trio is also apparent in their human chromosomal locations, with 
PANX1 and PANX3 located relatively close to each other on chromosome 11 (q21 and 
q24, respectively), and with PANX2 located on chromosome 22 (2).   
Topological similarities persist within the pannexin family, in which all three possess four 
transmembrane domains with cytosolic N- and C-termini (Fig. 1.1), similar to innexins and 
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connexins. The N-terminus and intracellular loop is found to be highly conserved between 
the three pannexin members while the C-terminus remains highly variable (5).  In addition, 
there are two cysteine residues preserved in each of the extracellular loops of pannexins 
(2). 
While possessing similar topological and sequence homologies, all three members present 
different mRNA and protein expression patterns in mammalian tissues (6). The most 
ubiquitous member is PANX1 with its mRNA and protein detected in most mammalian 
tissues (6-8). While its expression distribution was initially found to be restricted within 
the central nervous system specifically neurons and immature astrocytes within the cerebral 
cortex and cerebellum, there are new reports demonstrating PANX2 to be expressed in 
kidney tubular cells, seminiferous duct cells of the testis, excretory salivary glands, striated 
ducts, gastrointestinal tract glandular and epithelial cells, parietal cells, columnar epithelial 
cells, retina, lung and skin (6-9). Finally, PANX3 expression has been detected in the testis, 
stomach, spleen, salivary gland, lung, heart, duodenum, adrenal tissue, skeletal structures, 
skeletal muscle, lactating mammary tissue, sebaceous glands and the small intestine (2,6,7). 
As a result of its widespread expression pattern within human tissues, PANX1 is the most 
characterized member and will also be the main focus for the subsequent sections.  
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Figure 1.1 Topological structure of the pannexin family. All members possess cytosolic 
N- and C-termini, four transmembrane domains, two extracellular loops with two 
conserved cysteine residues in each loop, and one intracellular loop. Images were generated 
using human PANX1, PANX2, and PANX3 sequences and Protter program. 
1.2 Topological and Conformational Structure of 
PANX1 
The topological structure of PANX1 has been established to consist of four transmembrane 
domains (TM1-4) with two extracellular loops (EL1 and EL2), one intracellular loop (IL), 
and cytosolic N- and C-termini (NT and CT, respectively) (Fig. 1.1), along with two 
conserved cysteine residues within each EL (10). Six PANX1 monomers oligomerize 
within the endoplasmic reticulum (ER) to form a functional hexameric channel (11-13).  
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Using a voltage-activated Panx1 model, substituted cysteine accessibility analyses 
determined the pore structure of PANX1 channel to consist of the outer and inner portions 
of TM1 and EL1, respectively (14). Furthermore, they demonstrate that cysteine mutations 
of several residues near the end of the CT inhibited channel currents after thiol 
modification, suggesting that the CT plugs the pore. This follows with other studies 
demonstrating that Panx1 channel activity is regulated by the autoinhibitory CT in a ball-
and-chain manner (14-16). However, considering the different possible conformations 
Panx1 may undertake, a re-analysis demonstrated a loss of carboxy terminal reactivity of 
cysteines in K+-activated states (17). It has been suggested that in the ATP-permeable 
conformation, Panx1 may adopt a similar structure as ATP-permeable connexin channels 
do in which the NT lines the pore (18).  
The interactions between the different domains have not been fully elucidated but there are 
extensive reports on interactions of the CT with other domains. A study exploring the 
diverse functions of the CT demonstrated a short segment (I360-G370) to interact with the 
membrane as they noticed the α-helical content of a peptide spanning this region (G357-
S384) increased in the presence of membrane mimetic lipids (19). Furthermore, 
complementing the ball-and-chain model, they also demonstrated by using truncated Panx1 
constructs and peptides that I372-D379 residues of the CT are involved in pore closure.  
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1.3 Trafficking of PANX1 
Although ectopic expression systems demonstrate predominantly cell-surface localization 
of Panx1, the localization profile of endogenous Panx1 can vary across different cell types 
(6,20-22). Endogenously, Panx1 can be detected at the cell surface where its function has 
been mostly characterized to be an ATP release channel (23-25), and within the ER, where 
it has been demonstrated to function as a calcium-leak channel (26). 
Much of the research conducted on the trafficking pathways of Panx1 have focused on its 
anterograde pathway. The anterograde journey of Panx1 begins within the ER, where the 
channel receives high-mannose glycosylation (at N254) and subsequently traffics to the 
Golgi via anterograde Sar1-dependent COPII vesicles (27). Within the Golgi, Panx1 
receives further sugar modifications, forming the complex glycosylated species (27). From 
there, Panx1 then traffics to the cell-surface. While at the cell-surface, FRAP analyses 
revealed Panx1-EGFP to be highly dynamic and protein stability is facilitated through 
interactions between the CT and actin cytoskeleton (27).  
An emerging topic in Panx1 trafficking that awaits to be fully elucidated is retrograde 
trafficking of the channel. The first study conducted in this area demonstrated through 
inhibitor studies that Panx1 undergoes lysosomal degradation (28). While the same study 
demonstrated Panx1 was co-distributed with endocytic machinery including clathrin, AP2, 
dynamin II, caveolin-1, and -2, co-immunoprecipitation results failed to demonstrate direct 
interactions between Panx1 and the various components (28). Furthermore, Panx1 
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internalization was shown to be dynamin-II independent (28). Branching from this study, 
Boyce et al. demonstrated that extracellular ATP induces internalization of the channel to 
endosomes through a cholesterol-dependent process via an ATP-sensitive residue W74 
(29). Later work further demonstrated that this ATP-induced cholesterol-dependent 
internalization process required interactions between PANX1 and P2X7R (30).  
1.4 Diverse Functions of PANX1 
Despite their limited homology with innexins, pannexins do not form gap-junctions but 
rather single-membrane channels that function as a conduit for signaling molecules (31). 
However, there have been a few instances in which Panx1 has demonstrated gap-junctional 
behavior (26,32-34) but most reports appoint a single-membrane channel function for 
PANX1 (31), and have suggested that glycosylation of the channel provides a source of 
steric hindrance for gap-junction formation (28,35,36).  
The most well-characterized channel function of PANX1 is ATP release at the cell-surface 
where it has been demonstrated, that manipulation of channel activity, expression, and 
chemical modifications of PANX1 can affect overall ATP release (14,37-39). However, 
other laboratories have conflicting reports that demonstrated PANX1 to be devoid of an 
ATP release function (40) and is rather a chloride channel with no cation permeability  
(17,41,42), while one report demonstrated Panx1 to be a Ca2+-permeable ion channel (26). 
To reconcile the divergence of these results, it has been proposed that PANX1 can 
undertake different conformations dependent on the stimulus applied (17). When PANX1 
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was stimulated with physiological stimuli such as elevated extracellular potassium levels 
(23,24) or mechanical stimulation (23,43,44), PANX1 undertakes a conformational shape 
with a larger pore opening that favors both cation and ATP permeability. In contrast, when 
PANX1 is activated by positive membrane potentials (14) or caspase-cleavage of the 
autoinhibitory CT (13,45,46), the channel favors a smaller pore opening with anion 
permeability (17,41,42). While caspase-cleavage activation is a prevalent theme in cell 
death, voltage-activation through positive membrane potentials usually occurs during 
action potentials. Therefore, the latter activation method may only be physiologically 
relevant to neurons and muscle cells during repolarization. Overall, it is imperative to 
consider the different activated conformations PANX1 employs to understand interactions 
between different domains of the channel.  
1.5 Post-Translational Modifications of PANX1 
PANX1 is a dynamically altered protein that receives a diverse range of post-translational 
modifications (PTM) throughout its lifespan which has been shown to regulate various 
aspects of the channel from trafficking, protein stability, and channel activity. The 
following sub-sections will discuss the various PTMs PANX1 has been experimentally 
demonstrated to acquire. 
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1.5.1 N-linked Glycosylation  
The most well-characterized and significant PTM is N-linked glycosylation that occurs on 
N254 of the second extracellular loop (6,11,47). The state of glycosylation of monomeric 
PANX1 can be deciphered from PANX1’s protein banding pattern between approximately 
40 and 50 kDa when resolved in SDS-PAGE (Fig. 1.2). The banding pattern consists of the 
fastest-migrating non-glycosylated Gly0, the intermediate-running high-mannose Gly1, 
and the slowest-migrating complex glycosylated Gly2 species. Glycosylation first begins 
with the addition of the high-mannose glycosylation that occurs in the ER and is further 
modified to complex glycosylation in the Golgi (6,36). The extent of glycosylation impacts 
several properties of Panx1 including the efficiency for cell-surface trafficking, intermixing 
with other pannexin members, and channel function (6,22,47,48). While complex 
glycosylation is found predominantly at the cell-surface, this does not indicate that complex 
glycosylation is required for cell-surface trafficking (11,47). Gly0 and Gly1 still possess 
the ability to traffic to the cell-surface although to a lesser capacity relative to Gly2. 
Furthermore, interactions between Panx1 with Panx2 and Panx3 are affected by Panx1’s 
glycosylation state (47). Immunoprecipitation studies conducted by Penuela et al. shows 
that Panx2 interacts with only Panx1’s Gly0 and Gly1 as well as the glycosylation-deficient 
mutant N254Q, but not the Gly2 species. The authors also demonstrated weaker 
interactions between Panx1 and Panx3 which were enhanced when Panx1 lacked any 
glycosylation. The extent of glycosylation Panx1 receives is also variable in different tissue 
types, suggesting that regulation of glycosylation and consequently also channel function 
is dependent on the cellular context (6,11).  
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There are several reports of artificial and naturally occurring mutations that do not target 
N254 but can affect the glycosylation status of PANX1. To uncover possible glycosylation 
sites in addition to N254, Boassa and colleagues generated glutamine mutations of N204, 
N254, and N337, and noticed that N337Q banding profile did not result in Gly2 species but 
produced Gly0 and Gly1 (11). However, N337 site was excluded as an asparagine-
glycosylation site since it is found in the cytosolic C-terminus which would not be able to 
directly encounter the glycosyltransferases within the lumen of the ER and Golgi. In 
addition, mutations of extracellular cysteine residues (C66S, C84S, C245S, C264S) that 
have been generated to uncover regulatory mechanisms for channel activity revealed 
expression of predominantly Gly1 with minimal Gly0 and negligible amounts of Gly2 (49). 
These mutants also retained the ability to traffic to the cell-surface. Interestingly, when the 
cysteine mutants were tagged with EGFP at the C-terminus, there was a noticeable increase 
in Gly2 species, suggesting that attachment of fluorescent protein at the C-terminus may 
rescue the glycosylation deficiency induced by the cysteine mutations. Furthermore, they 
demonstrated that mutation of any of the extracellular cysteines resulted in no detectable 
channel activity. In a separate study also analyzing the role of nitrosylation on PANX1, 
transmembrane and intracellular cysteine mutants (C40A and C347A, respectively) also 
resulted in a protein banding pattern consisting primarily of Gly0 and Gly1 species with 
minimal Gly2 species (37). They also demonstrate that these mutants retain the ability to 
traffic to the cell-surface and both C40 and C346 experience S-nitrosylation that inhibits 
channel currents and ATP release. In a separate study that studied the role of patient-derived 
mutations that induced an oocyte-death phenotype that is later discussed in further details, 
also reported four mutants (C347S, Q392*, 21_23delTEP, K346E) that resulted in only 
Gly1 species and localization within the cell-surface (50). In addition to cell-surface 
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localization, the authors also noted localization of the four mutants within the Golgi and 
increased calreticulin expression, a chaperone protein for glycoproteins, suggesting the 
intracellular retention of misfolded PANX1 mutants. Similar to what was observed with 
the truncated mutant Q392*, expression of the RFP-tagged truncated mutant T307* also 
resulted in only Gly0 and Gly1 species. Overall, these studies indicate that proper protein 
folding and possibly nitrosylation of several cysteine residues of the channel may play a 
key role in PANX1’s complex glycosylation process.  
Figure 1.2: Anterograde trafficking pathway and glycosylation of PANX1. A. The 
nascent non-glycosylated PANX1 (Gly0) begins its journey within the ER where it receives 
high-mannose glycosylation forming the Gly1 species (red). Subsequently PANX1 traffics 
to the Golgi, where it receives further modifications to its glycosylation, forming the 
complex glycosylated Gly2 species (green). PANX1 then traffics to the cell-surface where 
it can mediate the release of signalling molecules such as ATP. B. Three distinct 
glycosylated PANX1 species can be identified via immunoblotting. 
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1.5.2 Phosphorylation  
An emerging PTM that has been shown to greatly regulate PANX1 channel function is 
phosphorylation. Several reports revealed that the Src family kinases (SFKs) are key 
modulators of PANX1 phosphorylation (51-55) and their affiliation has been implicated in 
neuronal excitotoxicity during ischemia amongst other functions (52-56). Interest in the 
SFK-PANX1 interactome was first generated when Iglesias et al. demonstrated that 
P2X7R-dependent Panx1 activation required Src activation (57). Inhibition of P2X7R-Src 
interaction via peptides resulted in inhibition of Panx1 channel currents while maintaining 
P2X7R activity. Subsequent studies explored PANX1 activation in neuronal excitotoxicity 
with Src-PANX1 at the helm (53,55). Weilinger et al. initially uncovered that during 
neuronal excitotoxicity, N-methyl-D-aspartate receptors (NMDARs) activated Panx1 via 
stimulating Src Kinase activity (55). Soon after, the mechanistic link leading to Panx1 
activation in neuronal excitotoxicity turned out to be phosphorylation of Y308, within the 
CT that was mediated by SFKs (53). Another group uncovered a tyrosine residue within 
the intracellular loop, Y198, that is phosphorylated by SFKs and leads to channel activation 
(52). Y198 phosphorylation has been shown to occur downstream of TNF-α stimulation in 
primary human venous endothelial cells. Y198 phosphorylation also has been shown to be 
stimulated by α-1-adrenoreceptors activation in vascular smooth muscle cells, leading to 
Panx1 activation (58). The same group also demonstrated that Y198 phosphorylation in 
vascular smooth muscle is constitutive in nature and occurs solely at the cell-surface. 
Surprisingly, in this context, Y198 phosphorylation is not mediated by α-1-adrenoreceptors 
activity but rather by SRC kinases (51). Overall, these accumulating studies of the receptor-
SRC-Panx1 interactome opens a branch of mechanistic explanations for the effects of 
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Panx1 in several physiological processes and pathologies such as epilepsy, synaptic 
plasticity, and astrocyte physiology.  
On the other hand, serine and threonine phosphorylation of Panx1 has not been studied as 
in depth as tyrosine phosphorylation. There are currently two studies that explored the 
presence and role of Ser/Thr phosphorylation. The first study demonstrated potentiated 
adult muscle cells via electrical stimulation experienced greater Panx1-mediated ATP 
release and Ser/Thr phosphorylation of Panx1 (59). Another study demonstrated that a 
nitric oxide donor, sodium nitroprusside, can inhibit Panx1 channel currents through a 
cGMP-PKG dependent-pathway that led to greater serine phosphorylation of Panx1 (60). 
It was suggested that phosphorylation of S206 mediates NO-mediated Panx1 inhibition as 
mutagenesis of this site abolished the inhibitory effects of sodium nitroprusside (60). 
1.5.3 Nitrosylation 
Another PTM that influences channel function is S-nitrosylation, the covalent 
incorporation of nitric oxide (NO) into cysteine thiols. The interest in S-nitrosylation of 
PANX1 was first generated when a study demonstrated that during oxygen-glucose 
deprivation in hippocampal neurons, inhibition of neuronal NO synthase resulted in NO- 
and redox-dependent blocking of PANX1 channel function (61). Subsequently, two studies 
proposed C282, C40, and C346 as possible sites of PTMs since mutagenesis of these sites 
resulted in reduced channel function (48,49,62). Extending from these findings, Lohman et 
al. demonstrated S-nitrosylation occurring on C40 and C346 as a regulatory mechanism to 
inhibit PANX1 currents (37).  
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1.5.4 C-terminus Caspase-cleavage 
The C-termini of the pannexin members is one of the least conserved domains of the 
channels (16) and it has been suggested that the divergent functional roles of pannexins 
may be derived from the differences between the C-termini. Regarding Panx1, irreversible 
caspase cleavage of the CT at D378 constitutively activates the channel by removing the 
autoinhibitory role of the CT (15,45). Furthermore, Panx1 truncated mutants lacking the 
CT (307) resulted in significantly lower cell-surface expression relative to wildtype (28). 
In addition, a chimeric protein consisting of Panx2 with its CT exchanged with the CT of 
Panx1 demonstrated altered sub-cellular localization profiles (63). In contrast with 
wildtype PANX1 and PANX2, which localized primarily at the cell-surface and 
endolysosomes, respectively, the chimeric PANX2(PANX1CT) resulted in a diffuse 
distribution across the cytoplasm (63).   
1.5.5 Oxidation 
A study that explored the effects of the inflammatory cytokine IFN- on Panx1 expression 
and function in human airway epithelial cells, revealed C426 to be a residue that may form 
disulfide bonds with other thiols (64). The noted inhibitory effects of H2O2 on Panx1 
channel function, which leads to the formation of reversible disulfide bonds between thiol 
groups, was abolished when this residue was mutated to serine (64).  
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1.6 PANX1 in Disease  
Not only is PANX1 expressed in virtually every tissue (1,2,6,32,65), but PANX1 also 
possesses the ability to release several signaling molecules that contribute to intercellular 
and autocrine signaling (17,23,26,41). The most well-known signaling molecules released 
by PANX1 include ATP (23), chloride (41), and calcium (26), all of which participate in 
countless signaling cascades that, when dysregulated, can induce or accelerate 
pathophysiological disorders. While the pannexin field has only been discovered in 2000 
(1) and the first report associating pannexins to a certain phenotype released in 2006 (54), 
the realm of diseases associated with pannexins, in particular PANX1, is exponentially 
expanding (10,66). 
Panx1 has been implicated in a large variety of diseases ranging from ischemia to 
inflammatory diseases and cancer. The contrasting roles of Panx1 in cancer is discussed in 
further details in the subsequent section. Many of the initial reports on the role of Panx1 in 
diseases focused on disorders of the nervous system with the first report demonstrating that 
in ischemic conditions Panx1 induces depolarization of hippocampal neurons leading to 
neuronal cell death (54). The same group also implicated Panx1 in epilepsy where they 
demonstrate that Panx1 is expressed in pyramidal neurons of the hippocampus and can 
augment epileptiform seizure activity after being activated by NMDAR stimulation. From 
these investigations, subsequent studies followed further establishing Panx1’s influence in 
ischemia and epilepsy (53,55,61,67,68).  
 
15 
 
Extracellular ATP, which can be derived from PANX1-mediated ATP release, also acts as 
a chemoattractant for immune cells and thus drive inflammation (69,70). As a result, 
another area of interest was to determine the function of Panx1 in inflammation. Initial 
reports of Panx1 promoting immune cell recruitment focused on apoptosis-induced ATP 
release from Panx1. Cells undergoing apoptosis activate Caspases 3/7 which then cleave 
the autoinhibitory C-terminus of Panx1 resulting in a constitutively-active Panx1 that leaks 
a trail of ATP for macrophages to follow for clearing cellular debris (45). A more complex 
model then followed in which PANX1-mediated ATP release is a crucial component of the 
NLRP3 inflammasome assembly, a protein complex that leads to the maturation and 
secretion of proinflammatory cytokines IL1β and IL18 and can also lead to pyroptosis (71). 
This pathway has been implicated in various pathophysiological disorders including 
cancer, osteoarthritis, autoinflammatory diseases, gout, type-2 diabetes, and more (72). 
However, it has been previously demonstrated by using Panx1-null mice that PANX1 is 
dispensable for NLRP3 inflammasome assembly (73). Furthermore, a group has also 
previously demonstrated that inhibition of Panx1, P2X7Rs, Asc or caspase activity 
inhibited inflammation-induced enteric neuron cell death in a mouse colitis model while it 
was not dependent on NLRP3 expression, suggesting that a separate Panx1-inflammasome 
complex may be implicated (74). Other pathophysiological disorders that Panx1 has been 
implicated in include promoting HIV infection (75), infertility (50), obesity (76), multiple 
sclerosis (77), migraine headaches (78), among others (10,66).  
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1.7 PANX1 in Cancer  
PANX1 appears to have contrasting roles in cancer depending on the tumour type and 
species being studied (20,34,79-83). There have been numerous studies demonstrating the 
prevalence of PANX1 upregulation in cancer cell lines and tumours relative to normal 
tissues (84-86) with a few cases presenting downregulation of PANX1 (80,87). Within 
cBioPortal, this dichotomy of differential expression levels presents as well, with some 
tumour types demonstrating amplification copy number variation such as bladder/urinary 
tract cancer, ovarian epithelial tumours, melanoma, cervical squamous cell carcinoma, 
prostate adenocarcinoma, and some with deep deletion copy number variation including 
seminoma, head and neck squamous cell carcinoma, and sarcoma, amongst others (88,89).  
In some cases, reducing the levels of PANX1 delays tumour progression. One study 
illustrated that reduction of PANX1 in the human glioma cell line U87-MG resulted in a 
significant reduction in proliferation (90). Similarly, another study by our  group 
demonstrated that knocking down mouse Panx1 expression in the aggressive mouse 
melanoma B16-BL6 cell line resulted in decreased proliferative and migratory capacities, 
increased melanin production, and decreased expression of malignant melanoma markers 
(91). Panx1 reduction in those cells fundamentally induced a reversion to a more 
melanocytic-like phenotype and a decreased tumorigenic profile. As of now, only one study 
demonstrated that elevated levels of Panx1 induced a tumour suppressive phenotype in 
which overexpressing Panx1-EGFP in mouse C6 glioma cells presented a tumour-
suppressive effect (34). However, they later also demonstrate that stable over-expression 
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of Panx1-EGFP in the same cell line accelerated glioma aggregates, a key feature of glioma 
progression, by stimulating the P2X7R pathway and in turn modifying the F-actin 
microfilaments (79).  
Expanding from the study uncovering the role of Panx1 in mouse melanoma, we explored 
the role of PANX1 in human melanoma to determine if similar effects would be observed 
in human melanoma cells (20). In this report, we have demonstrated that PANX1 mRNA 
expression was significantly higher from normal skin to primary tumours but did not differ 
significantly in mRNA and protein expression across different stages of human melanoma 
tumour progression (20). Similar to what was observed upon knocking down Panx1 
expression in mouse melanoma cells, knocking down PANX1 expression in human 
melanoma cells reduced their cell growth and migratory capacities as well as reduced 
expression of a malignant melanoma marker, β-catenin. To increase the therapeutic value 
of the findings of decreasing PANX1 expression in human melanoma, we administered 
PANX1 channel blockers, carbenoxolone and probenecid, to melanoma cells which 
similarly reduced malignant properties of the highly-metastatic A375-MA2 human 
melanoma cell line (20). Furthermore, another group demonstrated that administration of 
PANX1 channel blockers, 10Panx1 peptide and carbenoxolone, in mice injected with 
metastatic human breast cancer cells had reduced metastatic dissemination to the lungs by 
preventing the tumor-promoting effects of extracellular ATP (83). With the availability of 
the re-purposed drugs, probenecid and carbenoxolone (FDA-approved for gout and ulcers, 
respectively), as well as evidence demonstrating the effects that PANX1 inhibition presents 
in breast and melanoma cancers, PANX1 is becoming increasingly desirable as a viable 
therapeutic target in cancer.   
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1.8 Naturally Occurring PANX1 Variants and Mutations 
Most studies on PANX1 have focused on modulating expression levels and inhibiting 
channel function of PANX1, but few have studied the role of naturally occurring PANX1 
variants in the context of disease. As of now, there have been a total of six reports of PANX1 
variants (50,83,92-96), two of which are genome-wide association studies (GWAS) linking 
PANX1 variants with pathologies (95,96).  
One of the more commonly-reported PANX1 variant is the missense Q5H variant which 
has been shown to be associated with collagen-induced platelet reactivity in healthy 
subjects and displayed enhanced ATP release when ectopically-expressed (92). The group 
also later showed that the variant was not associated with platelet reactivity in stable 
cardiovascular patients in separate cohorts from the prior study (94). In a separate GWAS 
study identifying common variants associated with autism susceptibility risk, they found 
PANX1 to be implicated in cis by multiple SNPs that included Q5H (95).  Moreover, the 
variant Q5H was not associated with Schizophrenia in another GWAS study (96).  
Subsequent to studies on Q5H, the first report linking a PANX1 mutation to a disease was 
released (93). The authors associated a PANX1 missense variant R217H to a multisystem 
disorder diagnosed in a female consisting of skeletal defects, sensorineural hearing loss, 
intellectual disability, kyphoscoliosis, and primary ovarian failure. R217H displayed 
normal glycosylation and cell-surface trafficking but reduced dye-uptake, channel currents, 
and ATP release. Furthermore, co-expression of R217H with wildtype PANX1 did not 
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significantly reduce PANX1 channel currents, suggesting that R217H is not dominant-
negative to channel function. Although a causative role for R217H was not established, this 
was the first report of a germline PANX1 variant associated with a disease. Interestingly, 
R217H is also reported in two patient biopsies of prostate adenocarcinoma and 
glioblastoma multiforme cancers (88,89) and is identified as a single-nucleotide 
polymorphism (SNP) in dbSNP database that is reported in ExAC’s European (non-
Finnish) and South Asian populations, and in GnomAD’s European population (97,98). 
Therefore, the impact of R217H may be more widespread than previously thought.  
The first report of a PANX1 mutation associated with tumour aggressiveness has been 
shown to increase the metastatic efficiency of human breast cancer in areas of 
microvasculature (83). This somatic mutation produced a truncated form of PANX1, 
PANX11-89, containing only the amino-terminus, first transmembrane domain, and part of 
the first extracellular loop. PANX11-89 was found to be significantly enriched in metastatic 
breast cancer subclones CN-LM1A and MDA-LM2 relative to parental CN34 and MDA 
breast cancer cell lines. When Q89* was ectopically co-expressed with full-length PANX1, 
it led to significantly greater ATP release relative to cells ectopically expressing only full-
length PANX1. Furthermore, ectopic expression of only Q89* did not significantly alter 
the amount of PANX1-mediated ATP release relative to vector controls. Overall, this 
suggests that Q89* and wildtype PANX1 forms a hetero-oligomeric channel that enhances 
ATP release. The authors later showed that this enhanced ATP release led to the activation 
of downstream purinergic P2Y signaling to suppress deformation-induced apoptosis of 
breast cancer cells, a key feature of cancer metastasis. Ultimately, the presence of this 
mutation in metastatic breast cancer cells enhanced their efficiency to metastasize (83).  
 
20 
 
The largest study on germline PANX1 variants explored the role of patient-derived PANX1 
mutations from female patients experiencing familial or sporadic infertility (50). They have 
uncovered four PANX1 germline mutations using whole-exome sequencing, each from a 
different family experiencing oocyte death occurring either before or after in vitro 
fertilization. The four mutants (K346E, C347S, Q392*, and p.21_23delTEP), as 
aforementioned produced proteins that were hypo-glycosylated consisting of primarily 
Gly1 species and a lack of Gly2 species. Despite the lack of Gly2 species, the mutants 
maintained the capacity to traffic to the cell-surface in addition to some intracellular 
retention of the mutants within the Golgi. In addition, the four mutants enhanced ATP 
release and PANX1 channel currents. The authors also demonstrated the ectopic 
overexpression of Q392* and K346E in oocytes, induced oocyte death from 12 to 20 hours 
after cRNA injection in a dose-dependent relationship. Ectopic overexpression of C347S 
and 21_23delTEP in oocytes induced oocyte death 10 hours after in vitro fertilization. To 
discern whether the altered glycosylation profile induces oocyte death, they ectopically 
expressed N338Q mutant, of which produces solely Gly0 and Gly1 species, in oocytes and 
observed a similar oocyte death phenotype. Overall, this study demonstrated the important 
role PANX1 plays in oocyte development and that certain mutations may induce hypo-
glycosylation of PANX1 and enhance channel activity.  
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1.9 Using Cancer-derived PANX1 Somatic Mutations 
as a Source of Naturally Occurring Variants to Study 
PANX1 
A rich source of genetic variants lies within the cancer databases such as cBioPortal.org 
and the International Cancer Genome Consortium (ICGC) that have accumulated somatic 
mutations reported in tumour biopsies of cancer patients (88,89,99). As of today, 
cBioPortal.org has 108 somatic PANX1 mutations from various cancer types that are 
dispersed throughout the protein with higher densities of somatic mutations within the 
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intracellular loop and the C-terminus, two domains that are relevant for channel function 
(Fig. 1.3).  
1.10 Rationale and hypothesis 
We have previously demonstrated that inhibition or reduction of PANX1 in melanoma 
reduced their tumorigenic properties, demonstrating that PANX1 partakes in melanoma 
tumour progression (20,91). As a result, we analyzed variants derived from tumours of 
Figure 1.3: Somatic PANX1 mutations reported in tumours of cancer patients in 
cBioPortal cancer genomics database. A. A schematic of PANX1 denoting location of 
somatic mutations and indicating how many patients harboured a mutation at that site. B. 
Percentage of somatic mutations reported in each domain. 
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melanoma patients and from human melanoma cell lines in our laboratory. From this, we 
uncovered seven PANX1 variants (Q5H, Y150F, G168E, T176I, H190Y, S239L, and 
Q264*), whose effects on PANX1 function has not been characterized yet. Therefore, it is 
unknown if novel naturally occurring PANX1 variants reported in cancer may affect the 
biochemical and functional aspects of PANX1. I hypothesized that naturally occurring 
PANX1 variants prevent the normal function of PANX1 at the cell surface. 
1.11 Objectives  
 To analyse the impact of PANX1 variants on glycosylation, trafficking, 
phosphorylation, and channel activity of PANX1. 
 To assess the effect of PANX1 variants on cell growth and migration of cancer cells. 
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2.2 Abstract  
Pannexin 1 (PANX1) is a glycoprotein capable of forming large pore channels permeable 
to important signaling molecules such as ATP. In this study, we interrogated different 
domains of PANX1 by introducing naturally occurring variants reported in cancer and cell 
lines and assessed their impact on channel function. We discovered a novel tyrosine 
phosphorylation site at Y150, that when disrupted via a missense mutation resulted in 
hypo-glycosylation of PANX1, increased cell-surface localization, and dye uptake. We 
also discovered that the Q5H variant has a greater allele frequency than the wildtype Q5 in 
both global and cancer cohorts but was not associated with cancer aggressiveness. 
Furthermore, although Q5 and Q5H did not differ in N-glycosylation, localization or 
function in cancer cells, we uncovered that 90% of humans carry at least one Q5H allele, 
which is in fact the conserved ancestral allele of PANX1. Overall, this study demonstrated 
that other post-translational modifications have the capacity to affect cell-surface PANX1 
localization, and we identified a highly prevalent PANX1 variant in human populations. 
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2.3 Introduction 
Since its discovery in 2000 (1), Pannexin 1 (PANX1 in human, Panx1 in rodents), a 
channel-forming glycoprotein that mediates the release of signaling molecules below 1 
kDa in size, has been emerging as a key player in various physiological and pathological 
contexts ranging from blood pressure regulation (2,3), skin cell differentiation (4,5), 
facilitating neuronal cell death in ischemic conditions (7,8), apoptosis and inflammation 
(9-11), to regulating tumorigenic properties of cancers like melanoma (12,13). Depending 
on the cellular context and localization of the channel, PANX1 presents different functions. 
Most studies report PANX1 to be localized at the cell surface and is best-characterized to 
function as an ATP release channel (14) while others report PANX1 to be found 
intracellularly within the endoplasmic reticulum (ER) acting as an ER calcium-leak 
channel (15).  
PANX1 is characterized as a tetra-spanning protein with intracellular N- and C-termini and 
conserved cysteine residues within both extracellular loops (16), and several domains that 
regulate PANX1 trafficking and channel function have been identified. The intracellular 
loop and C-terminus have been demonstrated to undergo both tyrosine and serine 
phosphorylation which has been linked to overall channel function. Disruption of the 
tyrosine phosphorylation sites, Y198 or Y308, either by mutagenesis or peptide inhibition 
interferes with Panx1 interactions with N-methyl-D-aspartate receptors (NMDARs) and 
α1-adrenergic receptors, and affects channel function (17-19). The first extracellular loop 
regulates ATP-induced cholesterol-dependent internalization of the channel through its 
ATP-sensitive W74 residue (20) whereas the second extracellular loop undergoes N-linked 
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glycosylation on N254 which regulates cell-surface trafficking and intermixing with other 
Pannexin members (21). Due to the differential N-glycosylation that PANX1 undergoes, 
the protein is present as three distinct species: the non-glycosylated Gly0 species, the high-
mannose ER-resident Gly1 species, and the complex glycosylated Gly2 species which 
forms in the Golgi (22,23). While all three different species are capable of trafficking to 
the surface, Gly2 species are more prevalent at the cell membrane (21). PANX1 also 
undergoes S-nitrosylation at C40 of the N-terminus and C346 of the C-terminus of which 
inhibits channel function (24). Finally, the channel has been demonstrated to be regulated 
by the C-terminus in a “ball-and-chain” manner and proteolytic caspase cleavage of the C-
terminus results in a constitutively-active channel (10,25).  
Only a few recent studies have analyzed the effects of common and rare naturally occurring 
PANX1 variants. The first report associating a PANX1 mutation to a physiological disorder 
was a germline loss-of-function mutant, R217H, that was reported in a young female with 
intellectual disability, short stature, sensorineural hearing loss, primary ovarian failure, and 
kyphosis (26). In another report, a somatic nonsense mutation, Q89*, was found to be 
enriched in two metastatic breast cancer cell lines. The truncated protein Q89* was found 
to enhance PANX1-mediated ATP release only when co-expressed with full-length 
PANX1, and was shown to enhance the metastatic efficiency of breast cancer cells by 
reducing deformation-induced P2Y-mediated apoptosis in areas of microvasculature (27). 
A recent report revealed PANX1 germline mutations that caused familial or sporadic female 
infertility by inducing oocyte cell death. They uncovered four germline mutations (K346E, 
C347S, Q392*, and p.21_23delTEP) that produced gain-of-function, hypo-glycosylated 
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mutants consisting of predominantly Gly0 and Gly1 species (28). Finally, one variant that 
has been commonly reported is a missense variant, Q5H, which has been shown to be 
associated with collagen-induced platelet reactivity in healthy subjects and displayed 
enhanced ATP release when ectopically expressed (29). The same group later showed that 
the variant was not associated with platelet reactivity in stable cardiovascular patients in 
separate cohorts from the prior study (30). In a separate genome-wide association study 
(GWAS) identifying common variants associated with autism susceptibility risk, they 
found PANX1 to be implicated in cis using multiple single-nucleotide polymorphisms 
(SNPs) that included Q5H (31). Another GWAS study investigating associations of 
common pannexin variants with Schizophrenia found no associations between Q5H and 
Schizophrenia (32).  
Analyses of these and other naturally occurring variants may provide further information 
about the domains they reside in and how they might affect functional and biochemical 
properties of PANX1. In this study, we interrogated three motifs of the PANX1 polypeptide 
using single amino acid changes and evaluated their role in cell-surface PANX1 function. 
We introduced seven PANX1 naturally occurring variants reported in tumours of melanoma 
patients and human melanoma cell lines. These variants included Q5H, Y150F, G168E, 
T176I, H190Y, S239L, and Q264* that are in the N-terminus, intracellular loop, and 
second extracellular loop of the PANX1 polypeptide. 
By probing these important motifs, we have uncovered Y150 as a novel tyrosine 
phosphorylation site that can alter N-glycosylation, trafficking and channel function. In 
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addition, Q5H is equal to Q5 in channel function, glycosylation, and cell-surface 
localization in human breast cancer cells. We also discovered Q5H to have a higher allele 
frequency than Q5 in cancer cohorts but was not associated with cancer aggressiveness. 
The higher allele prevalence of Q5H than Q5 was also demonstrated in global cohorts and 
has emerged to be the ancestral allele at this locus.  
2.4 Results 
Y150F alters normal PANX1 protein banding pattern indicative of glycosylation states 
Seven PANX1 variants identified in tumors of melanoma patients and several established 
cancer cell lines (Fig. 2.1A; Suppl. Fig. 2.1) in addition to wildtype (denoted as Q5 from 
here forth) were assessed initially for their effects on PANX1 glycosylation and 
localization to investigate any changes that may result in altered PANX1 function. 
Differential N-glycosylation of PANX1 can occur and be preliminarily inferred by 
observing the protein banding pattern of PANX1 consisting of Gly0, Gly1, and Gly2 
species (22).  
Due to their relatively low Panx1 endogenous expression (33) and large cytoplasm for 
identification of PANX1 localization, normal rat kidney (NRK) cells were used to 
transiently over-express the various PANX1 variants. Most of the variants, except for 
Y150F and Q264*, produced PANX1 banding patterns like Q5 consisting of Gly0, Gly1, 
and Gly2 (Fig. 2.1B). Y150F instead produced predominantly Gly1 species with notably 
reduced Gly2 and Gly0 species. The Q264* variant, which produces a truncated mutant 
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lacking the carboxyl-terminus and thus required detection with an antibody targeting the 
amino-terminus, was not detected at the protein level (Fig. 2.1C), despite the presence of 
mRNA transcripts encoding the mutant (data not shown). Moreover, immunofluorescence 
analyses revealed that all PANX1 variants localized at the cell surface in NRK cells (Fig. 
2.1D). As a result of Y150F altering the normal PANX1 banding pattern and Q5H being 
previously reported to enhance PANX1-mediated ATP release (29), we chose these two 
variants for further investigation.  
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To eliminate all endogenous wildtype PANX1 that may facilitate the trafficking and 
glycosylation of the mutants, we generated two cancer cell lines engineered using 
CRISPR/Cas9 to delete the PANX1 gene and eliminate PANX1 expression (KO): the 
human triple-negative breast cancer cell, Hs578T(KO), and human melanoma cell line 
A375P(KO). Transient overexpression of Q5H and Y150F reproduced a similarly altered 
PANX1 banding pattern of Y150F consisting of predominantly Gly1 with minimal Gly2 
species (Fig 2.2A) and cell-surface localization as observed in NRK cells even in the 
absence of endogenous PANX1 (Fig. 2.3A).  
The differential banding pattern of Y150F species in NRK, Hs578T(KO), and A375P(KO) 
cells indicated that Y150F may be experiencing a differential glycosylation process or 
other post-translational modifications. To confirm N-linked glycosylation is present 
Figure 2.1: Y150F alters normal banding patterns of PANX1 in NRK cells. A. 
Schematic of PANX1 polypeptide demonstrating location of PANX1 variants Q5H, Y150F, 
G168E, T176I, H190Y, S239L, and Q264*. Schematic was generated using Protter (6). 
EV: empty-vector, NT: amino-terminus, TM: transmembrane, EL: extracellular loop, CT: 
carboxyl-terminus, IL: intracellular loop. B.  NRK cells were transfected to transiently 
overexpress selected PANX1 variants and PANX1 banding pattern was assessed 72 hours 
post-transfection. Immunoblotting revealed Y150F to disrupt normal banding pattern of 
PANX1, resulting in primarily Gly1 with minimal Gly0 and Gly2 species. C. PANX1 
protein was not detected in NRK cells with Q264* using two different antibodies against 
the CT or the NT. The molecular weight of Q264* is expected to be approximately around 
29 kDa. GAPDH was used as a loading control. Protein sizes in kDa. D. 
Immunofluorescence analyses revealed all variants appeared to localize to the cell-surface 
upon ectopic expression in NRK cells. Bar: 10µm.  
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throughout the various bands of Q5H and Y150F, we incubated protein samples from 
Hs578T(KO) overexpressing empty vector (EV), Q5, Q5H, and Y150F with PNGase F, 
which recognizes and cleaves all N-linked glycosylation that is manifested in Gly1 species 
and maintained in Gly2 species of wildtype PANX1. This resulted in the downwards shift 
of all bands to Gly0, indicating the presence of N-linked glycosylation in all bands above 
Gly0 (Fig. 2.2B). Furthermore, we applied EndoH, a de-glycosylation enzyme that cleaves 
only high-mannose glycosylation as encountered in Gly1 species. Application of EndoH 
to EV, Q5, Q5H, and Y150F protein lysates resulted in complete digestion and downwards 
shift of Gly1 band to Gly0 for Q5 and Q5H samples but only a partial digestion of Gly1 
species in Y150F lysates (Fig. 2.2B), indicating Y150F receives a different editing of the 
high-mannose species subsequent to its addition.  
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Figure 2.2: Y150F produces a Gly1 species that is partially resistant to EndoH de-
glycosylation. A. Hs578T(KO) cells and A375P(KO) cells devoid of PANX1 were used 
to transiently over-express empty-vector (EV), Q5, Q5H, and Y150F and assessed for 
changes in PANX1 banding pattern via immunoblotting. Western blot analyses revealed 
that Y150F disrupted the normal banding pattern in both cell lines, resulting in primarily 
Gly1 species. B. PNGaseF digestion of protein lysates from Hs578T(KO) transiently 
overexpressing PANX1 variants and controls (N=3). EndoH digestion of protein lysates 
from Hs578T(KO) transiently overexpressing PANX1 variants and controls, resulted in the 
downwards shift of Gly1 species of Q5 and Q5H to Gly0 band. In contrast, Y150F was 
partially resistant to EndoH digestion, even when the amount of Endo H was doubled (++). 
GAPDH was used as a loading control. Representative blots of N=3. 
Greater amounts of Y150F Gly1 species detected at the cell-surface  
Regulation of PANX1 function is dependent on various factors including the amount of 
PANX1 localized at the cell surface. Immunofluorescence analyses revealed the capacity 
of all variants to traffic to the cell surface in NRK (Fig. 2.1D), Hs578T(KO), and 
A375P(KO) cells (Fig. 2.3A). To quantify the amount of PANX1 variants at the cell-
surface, cell-surface protein biotinylation was performed on Hs578T(KO) transiently 
expressing EV, Q5, Q5H, and Y150F. Quantification of cell-surface PANX1 protein 
biotinylation  revealed Y150F to be more abundant at the cell surface relative to Q5 and 
Q5H (Fig 2.3B-C). While Q5 and Q5H presented significantly greater Gly2 species than 
Gly0 and Gly1, Y150F demonstrated similar amounts of Gly2 and Gly1, albeit both at 
significantly greater quantities than Gly0 (Fig. 2.3D). Furthermore, in contrast with Q5 and 
Q5H in which greater Gly2 species were detected at the cell surface, greater Gly1 and less 
Gly2 species were detected in pull-down of cell-surface proteins of Y150F (Fig. 2.3E). 
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Contrasting with the previous finding, when higher amounts of Y150F plasmid DNA were 
used in the transfection (5x increase), we noted that the greater over-expression of Y150F 
in NRK cells resulted in predominantly intracellular localization of the protein which 
differs from the cell-surface localization profile of Q5 even at higher DNA concentrations 
(Suppl. Fig. 2.2A). However, the altered banding pattern of Y150F remained the same as 
described above (Suppl. Fig. 2.2B). Furthermore, greater Y150F expression also 
significantly reduced cell viability relative to EV- and Q5-transfected NRK cells while 
lower expression of the mutant did not affect viability (Suppl. Fig. 2.2C).  
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Figure 2.3: Greater amounts of Y150F Gly1 localize at the cell-surface relative to Q5 
and Q5H. A. Hs578T(KO) and A375P(KO) transiently overexpressing EV, Q5, Q5H, and 
Y150F were assessed for PANX1 localization via immunofluorescence. (N=3), Bars: 
20µm. B. Cell-surface protein biotinylation was performed on Hs578T(KO) cells 
transiently over-expressing PANX1 variants (One-way ANOVA; * p < 0.05; N=3). N-
Cadherin was used as positive cell-surface control and GAPDH as a negative control. C. 
Quantification of cell-surface biotinylation assay of Hs578T(KO) transiently 
overexpressing PANX1 variants (N=3). D. Quantification of individual bands of 
biotinylated PANX1 relative to total biotinylated PANX1 protein in input lysates (One-
way ANOVA; N=3; ****P < 0.0001). E. Quantification of individual PANX1 bands 
(Gly0, 1, 2) relative to total biotinylated PANX1 (One-way ANOVA; N=3; **** p < 
0.0001) 
Y150 is a tyrosine phosphorylation site of PANX1 
The Y150 site (146-LDKVYNRAI-154) has been predicted to be phosphorylated by 
epidermal growth factor receptor (EGFR), insulin receptor (INSR) and sarcoma (SRC) 
kinase,  as determined by the phosphorylation prediction software NetPhos 3. (34). 
Phosphorylation of Y150 (Y150-P) of PANX1 was also previously identified in a high-
throughput screening study for tyrosine-phosphorylated proteins in a human leukemic cell 
line identified by mass spectrometry (35).  
To determine whether Y150 is phosphorylated in Hs578T(KO) cells ectopically expressing 
PANX1, we immunoprecipitated PANX1 species from Hs578T(KO) cells overexpressing 
EV, Q5, Q5H, or Y150F and sent individual band samples from the different glycosylated 
species (Gly-0, Gly-1, and Gly-2) for Electrospray Ionization (ESI) mass spectrometry to 
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identify peptides containing phosphorylated Y150, non-phosphorylated Y150, and 
peptides containing Y150F (Fig. 2.4A; Suppl. Fig. 2.3). 
ESI analyses revealed the presence of the phosphorylated Y150-P peptide within Gly-2 
species along with the non-phosphorylated Y150 peptide in Gly-0, Gly-1 and Gly-2 in Q5 
and Q5H samples. Y150F was detected only in Gly-0, Gly-1, and Gly-2 bands of Y150F, 
and no Y150-P peptide was detected in any of the Y150F bands (Fig. 2.4B).  
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Figure 2.4: Y150 is a tyrosine phosphorylation site of PANX1. A. Y150 is predicted to 
be a tyrosine-phosphorylation site by NetPhos3.1 Server. Predicted kinases of the Y150 
site include Epidermal Growth Factor Receptor (EGFR), Insulin Receptor (INSR), and 
SRC kinases. B. PANX1 was immunoprecipitated (IP) from Hs578T(KO) transiently over-
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expressing EV, Q5, Q5H, or Y150F and bands from SDS-PAGE gel representing Gly-0, 
Gly-1, and Gly-2 of PANX1 were sent for ESI-MS processing and analysis. (N=1) C. 
Analyses of ESI demonstrating identification of Y150-containing PANX1 peptides. 
Y150F enhances basal dye-uptake while Q5H does not differ functionally from Q5 
We also sought out to determine if Q5H and Y150F influences PANX1 channel activity as 
determined by basal (non-stimulated) uptake of the cyanide monomeric dye YO-PRO1 and 
whole-cell patch clamp electrophysiology recording. Comparing the functional outcome 
from transient transfections of EV, Q5, Q5H, and Y150F in Hs578T(KO) we observed 
significantly greater dye uptake in Y150F-transfected cells, and no significant difference 
in unstimulated dye uptake from EV, Q5, and Q5H expressing cells (Fig. 2.5A). Whole-
cell patch clamp recordings on HEK293T cells transiently transfected with Q5 and Q5H 
revealed no significant differences in channel activity, and both peak currents were reduced 
with the channel blocker carbenoxolone (CBX) (Fig. 2.5B-C). HEK293T cells transfected 
with Y150F experienced significant cell death in those cells, and as a result were not 
included in electrophysiology recordings.  
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 Figure 2.5: Y150F enhances basal dye uptake while Q5H does not differ functionally 
from Q5. A. Basal (unstimulated) dye-uptake of YO-PRO1 was performed on 
Hs578T(KO) cells transiently over-expressing EV, Q5, Q5H, and Y150F. Flow cytometry 
analyses revealed a significantly greater amount of dye-uptake in Y150F transfected cells 
(N=3, n=9, ***P < 0.001). A representative western blot demonstrating protein expression 
levels of Hs578T(KO) cells transiently overexpressing PANX1 variants (EV: empty 
vector) (N=3). B. Representative current-voltage relationships recorded in the presence or 
absence of carbenoxolone (CBX, red) in HEK 293T cells expressing Q5 or Q5H. C. 
Summary of ramp currents recorded at +100 mV from Q5- and Q5H-expressing HEK293T 
cells (Unpaired two-tailed T-test; N=6). 
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Stable overexpression of Q5H does not affect cellular localization, dye-uptake, cell 
growth, and migration relative to Q5 controls  
To assess if Q5H differs from Q5 regarding channel activity, and if it affects cancer cell 
properties when expressed, we generated stable clones of Hs578T(KO) overexpressing Q5 
or Q5H at similar protein expression levels (Fig. 2.6A). Immunofluorescence analyses 
demonstrate that Q5 and Q5H localize at the cell surface when stably expressed (Fig. 2.6B). 
Channel activity, assessed with basal dye uptake of YO-PRO1, did not differ significantly 
between Hs578T(KO) stably expressing Q5 or Q5H but both were significantly higher than 
non-transfected control (Fig. 2.6C).  
Furthermore, we characterized if the expression of Q5H affects migration and cell growth 
of cancer cells and found that they did not differ significantly between Hs578T(KO) stably 
overexpressing Q5 or Q5H but migration was significantly lower in both stable clones 
compared to controls that had not undergone transfection and selection (Fig. 2.6D-E). 
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Figure 2.6: Stable-overexpression of Q5H in Hs578T(KO) cells does not differ in dye-
uptake, migration, and cell growth from Q5 controls. A. Stable clones of Hs578T(KO) 
overexpressing Q5 or Q5H at similar protein levels were generated. GAPDH used as 
loading control. B. Immunofluorescence analyses (PANX1, green) demonstrate that Q5 
and Q5H both localize at the cell surface in stable clones. Bar: 20 µm. C. Q5H did not 
differ significantly from Q5 in basal uptake of YO-PRO1 dye but both were significantly 
higher than non-transfected controls (KO). D. Cell growth assay was performed by 
assessing number of viable cells that excluded Trypan blue dye. Cell counts did not differ 
significantly between Hs578T(KO) stably over-expressing Q5 and Q5H and non-
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transfected controls. E. Cells were grown to confluence on a petri dish and a scratch was 
made, upon which the area cells migrated into after 15 hours was recorded. Migration did 
not differ significantly between Hs578T(KO) stably over-expressing Q5 and Q5H but both 
were significantly lower than non-transfected/non-selected controls. N=3, **** P < 0.0001. 
Q5H has a greater allele and homozygosity frequencies than Q5 in cancer cohorts  
Finally, we sought to determine if there may be meaningful correlations between the 
Y150F and Q5H variants and patients with cancer since these variants were reported in 
cancer databases. Analyses of cancer cohorts deposited in cBioPortal.org and the 
International Cancer Genome Consortium databases (36-38) revealed Y150F to be a rare 
variant detected in only one melanoma biopsy from The Cancer Genome Atlas (TCGA) 
skin cutaneous melanoma (SKCM) cohort. There is only one other reported missense 
variant at Y150 across 40,317 sequenced cancer patients in cBioPortal: a Y150C somatic 
mutation in a bladder urothelial carcinoma biopsy from TCGA’s Bladder Urothelial 
Carcinoma dataset (36,37) (Suppl. Fig. 2.1B).  
In contrast, the Q5H variant was detected in ten patients with different tumour types within 
cBioPortal and the International Cancer Genome Consortium databases with the majority 
of patients from a colorectal cancer dataset with Chinese origin (36-38). Since cancer 
genomics databases only report somatic mutations, and not genetic polymorphisms such as 
Q5H, we delved deeper into the whole exome sequencing of patients within a colorectal 
cancer dataset with Korean descent as a comparable dataset with similar race. Interestingly, 
the allele frequency of Q5H was significantly higher than Q5 in both normal and colorectal 
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tumour samples, but there remained no significant differences of Q5H allele frequency 
between normal and tumour samples (Fig. 2.7A). We also assessed TCGA’s SKCM cohort 
that consists of 470 patients with matched normal blood or solid tissue, primary solid 
tumour, and metastatic samples. The allele frequency of Q5 and Q5H was assessed and the 
genotype of each individual was inferred by the presence and/or absence of the Q5 and 
Q5H alleles. Similar to what was seen in the colorectal cancer dataset, the allele frequency 
of Q5H was significantly greater than Q5 in both normal and tumour samples (Fig 2.7B). 
Despite the greater allele frequency of Q5H, there was no significant differences in overall 
and disease/progression-free survival between individuals who presented Q5|Q5, Q5|Q5H, 
and Q5H|Q5H genotypes (Fig. 2.7F-G). In correspondence with the previous finding, there 
were also no significant differences in Q5H allele frequency between tumours of different 
tumour, lymph node, and neoplasm stages (Fig. 2.7C-E) except for a significant reduction 
in Q5H allele frequency in tumours with N1 neoplasm disease stage relative to N0 (Fig. 
2.7E).  
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Figure 2.7: Higher Q5H allele frequency than Q5 in colorectal and skin cutaneous 
melanoma cancer cohorts. A. Significantly higher Q5H allele frequency than Q5 was 
found in matched colorectal samples from microarray study PRJNA246431. B. The allele 
frequency of Q5 and Q5H was assessed in normal, primary solid tumour, metastatic 
tumours of melanoma patients from TCGA’s SKCM cohort. Q5H allele frequency was 
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found to be significantly higher than Q5 allele frequency in normal tissues and metastatic 
tumours but not in primary solid tumours. (Letters denote significant differences; One-way 
ANOVA). C-E. Q5H allele frequency was assessed across different stages of neoplasm 
disease, neoplasm lymph node disease, and tumour stages of skin melanoma patients. (One-
way ANOVA; N=470; * P< 0.05) F-G. Overall and disease-free progression survival did 
not significantly differ between QQ, QH, and HH skin melanoma patients.  
Q5H has a greater allele and homozygosity frequencies than Q5 in global cohorts  
To assess the allele frequencies of Q5H and Y150F in global cohorts, we obtained data 
from the ExAC Browser Exome Aggregation Consortium (39), an assembly of data from 
a variety of genome-sequencing endeavors that includes 60,706 unrelated individuals 
sequenced for disease-specific and population-genetic studies. Within ExAC database, the 
Y150F variant was not detected however a Y150H missense variant was, albeit at a very 
low allele frequency of 8.24e-06 (39). Like what was seen in cancer cohorts, Q5H also 
presents a higher allele frequency than Q5 in global cohorts with the highest allele 
frequency of 83.83% in Latino populations followed by African populations with an 
average of 82.92% (Fig. 2.8A-B). Genotype frequencies of 1000genomes (phase 3) 
populations, a genome-sequencing endeavor that assembled the genomes of 2,504 
individuals across 26 different populations across the world, were also assessed and 
revealed that approximately 84% of individuals possessed at least one copy of the Q5H 
allele, demonstrating its high prevalence in human populations (Fig. 2.8C-D). 
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Q5H is highly conserved amongst vertebrate species and is the ancestral allele  
The prevalence of the Q5H allele globally and within cancer cohorts indicated that Q5 
could be a derived allele, one that arose through evolution as a result of a mutation, and 
points to Q5H as the ancestral allele. To determine if Q5H is the ancestral allele, we 
compared it to the allelic state of our last common ancestor, the chimpanzees, as an 
approximation (40). Comparing the nucleotide codon encoding the fifth amino acid of 
PANX1 across 31 eutherian mammal species including the chimpanzees and other species 
used to study PANX1, we uncovered that the RefSeq of all assessed species, excluding 
humans, possessed nucleotide codons that only encoded for Histidine (Fig. 2.8E).   
Furthermore, some studies have noted that the highest frequency for ancestral alleles are 
within African populations (41) and African populations have the second highest Q5H 
allele frequency and highest percentage of Q5H homozygous individuals in the 
1000genomes project (Fig. 2.8B,D). These findings reveal that Q5H is not only the most 
representative variant of PANX1 within human populations but also the ancestral allele at 
this locus for PANX1.  
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Figure 2.8: Higher Q5H allele frequency than Q5 in global cohorts. A. A map 
representing the distribution of Q5 and Q5H alleles in various populations from the 1000 
Genomes Project. Polymorphism rs1138800 (Q5H) was assessed and map was generated 
by the Geography of Genetic Variants Browser (v0.4 beta). B. Allele frequency of Q5H 
found in diverse populations. Data was extracted from the ExAC Browser Beta. C-D. The 
genotype frequency of individuals sequenced in the 1000 Genomes Project demonstrate 
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that most individuals (~89%) possess at least one allele copy of Q5H.  E. Ensembl 
phylogenetic context alignment revealed Q5H is a highly conserved site amongst 
vertebrate species with humans being the only species with Q5. 
2.5 Discussion  
Given its widespread expression within the human body along with the wide range of 
signaling molecules it is permeable to, it is not surprising that PANX1 has been implicated 
in various pathological disorders such as ischemia, HIV infections, melanoma, and others 
(7,12,13,42). While most studies explored the effects of altering expression or inhibition 
of PANX1, only six investigations have explored the effects of coding variations on 
channel function in the context of disease (26,28-32). This report studied the influence of 
two naturally occurring PANX1 variants, Q5H and Y150F, on the trafficking and function 
of PANX1. Overall, we uncovered a novel tyrosine phosphorylation site that influences 
normal glycosylation and trafficking, and a highly prevalent ancestral PANX1 variant that 
contrary to current knowledge is the most common PANX1 found in humans. 
The role of Y150 phosphorylation  
Mutagenesis of the Y150 residue resulted in disruption of Y150 phosphorylation and 
alterations to normal N-glycosylation and trafficking of the protein. Although the 
phosphorylated and non-phosphorylated Y150 peptides were detected only in the Gly2 
states of Q5 and Q5H, the spatiotemporal pattern of Y150 phosphorylation remains 
uncertain. The resistance to EndoH de-glycosylation acquired by Y150F and the reduction 
in Gly2 species production, suggests that Y150 phosphorylation may establish a 
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glycosylation pathway leading to complex glycosylation of the protein by either interacting 
with N-glycosyltransferases or altering protein folding and/or stability. Disrupting its 
phosphorylation by mutating the residue to phenylalanine led to the formation of a hypo-
glycosylated species and enhanced the ability of PANX1 to localize at the cell surface in 
greater amounts than both Q5 and Q5H. It remains unknown if the greater amounts of Gly1 
at the cell-surface are the EndoH-resistant or EndoH-sensitive Gly1 species of Y150F. 
Nonetheless, this enhanced cell-surface localization of Gly1 and relatively low amounts of 
cell-surface localization of Gly2 is contrary to previous reports demonstrating that Gly2 
has a greater capacity to localize at the cell-surface than Gly1 and Gly0 species (21). 
Therefore, this suggests that the Gly2 species expressed in Y150F may not be complex 
glycosylated but rather experiences another type of glycosylation modification such as a 
‘hybrid glycosylation’ (43) that may accelerate trafficking to the cell-surface or further 
stabilize the channel at the cell-surface. Furthermore, Sang et al. (28) has previously 
unveiled four hypo-glycosylated PANX1 mutants that induced increased expression of 
calreticulin, a chaperone protein that facilitates glycoprotein folding. This suggests that 
proper protein folding facilitates editing to complex glycosylation and that, in the case of 
Y150F, the lack of phosphorylation or merely the mutation, may alter protein 
folding/stability and favor an alternate glycosylation-editing pathway.  
Previous evidence of PANX1 tyrosine phosphorylation, specifically on Y198 and Y308 of 
mouse and rat Panx1, respectively, demonstrated phosphorylation required interactions 
with the Src Family Kinases (SFKs) (18,24,44,45). Administration of interfering peptides 
against SFK consensus phosphorylation sites of Y198 and Y308 sites abolished Panx1 
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activation mediated by SFKs (17,18). Furthermore, the same group also demonstrated that 
Y198 phosphorylation occurs at the cell-surface and was dependent on SFK activity (46) 
and that tyrosine phosphorylation of either Y198 or Y308 activated channel activity, 
demonstrating that phosphorylation modulates channel activity (17,18). While Y150 is 
predicted to be phosphorylated by SFKs (among other kinases), it may produce an opposite 
effect than Y198 and Y308 phosphorylation as mutagenesis of Y150 further enhanced dye 
uptake. However, it is difficult to attribute this characteristic merely to enhanced channel 
activity as there were significantly more Y150F channels at the cell-surface to mediate dye-
uptake than Q5 or Q5H channels. This is further complicated by the differential 
glycosylation Y150F receives thus demonstrating that glycosylation may also play a key 
role in channel function. Differential glycosylation of PANX1 via other naturally-
occurring variants has been previously demonstrated to enhance channel activity in mouse 
germinal vesicle oocytes (28). Thus, this suggests that phosphorylation is not the only 
indicator of cell-surface channel activity. Finally, since ectopic over-expression Y150F 
reduces cell viability in NRK cells, it is possible that the enhanced uptake of the YO-PRO1 
dye, of which is also commonly used a marker for apoptosis (47), may be due to Y150F 
potentially driving cell death pathways.  
Possessing a Y150F variation in the context of cancer can have different effects depending 
on the expression level of the mutant. Lower expression levels of Y150F can result in 
greater overall cell-surface channel function thus potentially promoting tumorigenic 
properties, depending on tumor type, while higher expression levels can lead to greater 
intracellular localization of the channel and reduced cell viability. Therefore, not only does 
 
61 
 
the presence of the variation needs to be considered but also the amount of the mutated 
protein. As aforementioned, only two cancer patients harbor mutations that disrupt the 
Y150 site, that includes Y150F and Y150C mutations (36,37). In both cases, the allele 
frequency for the mutations are less than 0.5, suggesting heterozygosity with wildtype 
PANX1 which may produce effects different than was observed in this study. Further 
investigation is required to determine the effects of co-expressing wild-type PANX1 with 
Y150F on cell-surface trafficking, channel function, and cell viability. Since only two 
patients possess a mutation at the Y150 site along with many other mutations in other 
genes, it is difficult to determine the effects of these mutations on the disease status of these 
patients.  
Q5H in cancer  
What initiated our interest in Q5H was a previous report demonstrating that the Q5H 
variant was enriched in healthy Caucasian males with platelets that were hyper-reactive to 
collagen (29). Interestingly, this study demonstrated that ectopic expression of Q5H in 
Chinese Hamster Ovary cells resulted in a greater basal and K+-activated ATP release than 
Q5 and controls (29). With the emergence of numerous reports demonstrating the tumor-
promoting effects of PANX1 (12,13,27,48,49), along with the finding that Q5H promoted 
ATP-release in a normal cell line and finally that Q5H was present in cancer patients (36-
38) and cancer cell lines, we then developed the premise that Q5H may play a role in 
promoting tumorigenic properties. Contrary to our hypothesis, Q5H did not impact channel 
activity when expressed in cancer and HEK293T cells. However, it is important to note 
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that Molica et al. (29) used basal and K+-activated ATP release to assess for PANX1 
channel activity whereas we employed basal dye uptake and voltage-activation whole-cell 
patch-clamp electrophysiology. The different stimuli used, voltage activation and elevated 
extracellular K+ conditions, have been previously shown to promote different 
conformational shapes (50,51); the former involves the C-terminus lining the pore whereas 
the latter does not. It has been suggested that elevated extracellular K+ conditions which 
favors ATP-permeability may induce a conformation similar to ATP-permeable Connexin 
channels in which the N-terminus lines the pore of the channel (14,52). Therefore, the 
divergence in channel activity between these two studies may be attributed to the different 
techniques used to measure channel function, and we cannot rule out potential differences 
between Q5 and Q5H in other cell contexts, with other functional assays and stimulation. 
Although Q5H allele frequency was significantly greater than Q5 in cancer cohorts, this 
was also observed in global cohorts. In order to compare the allele frequencies between 
cohorts, we need to take into consideration the racial distribution as the allele frequency of 
Q5H can vary greatly across different racial groups of global cohorts with the highest of 
83.83% in Latino populations and lowest of 61.13% in South Asian populations. We chose 
a melanoma cohort because we have previously demonstrated that inhibition or reduction 
of PANX1 in human melanoma cells reduced their tumorigenic profile, thus implicating 
PANX1 to play an influential role in human melanoma tumour progression (12). In 
TCGA’s SKCM cohort 447 of 470 samples belonged to white individuals along with 12 
Asian, 1 African American individual in addition to 10 non-reported samples. As a result, 
a suitable comparison would be the Non-Finnish European population in ExAC dataset. 
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Even though the mean Q5H allele frequency of normal samples from TCGA SKCM is 
slightly lower than that of ExAC’s (58.72% vs 63.53%), it is important to note that the 
small difference may arise from the different methodologies used to assess allele 
frequencies. Further corroborating this, ectopic expression of Q5H in cancer cells did not 
enhance PANX1 channel function, cell growth and migratory capacities of breast cancer 
cells. Therefore, while Q5H may increase channel function and play a role in platelet 
aggregation (29), our findings suggest that it may not have the same gain-of-function effect 
in this breast cancer cell line.  
Our discovery that Q5H is a highly conserved and more prevalent ancestral allele than Q5, 
which is annotated in various genomic and protein sequencing databases to be the best and 
most representative allele, highlights the necessity to thoroughly analyze and confirm 
genomic sequences that are representative of the overall population. Ironically, when 
human PANX1 was fully sequenced in RefSeq in 2003 by Baranova et al. (16) (Accession 
No. AF398509.1), the PANX1 mRNA sequence contained the codon encoding for histidine 
in the fifth amino residue. However, currently the PANX1 mRNA sequence (Accession 
No. NM_015368.4) in RefSeq contains the codon that encodes for glutamine at the fifth 
residue. This has led to numerous studies over the years utilizing the derived allele that is 
less prevalent than the ancestral Q5H allele. As a result, future studies on human PANX1 
need to take into consideration the two prevalent and divergent variants Q5 and Q5H, (or 
rather, Q5 and H5), since it remains unknown how they may differ in other cellular 
contexts.  
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In conclusion, by exploring various naturally occurring PANX1 variants, we have 
uncovered two that revealed unknown characteristics of the widely expressed protein. The 
rare variant Y150F revealed a phosphorylation site that affects glycosylation, trafficking, 
and function of PANX1, while the common variant Q5H had similar function to Q5 and 
turned out to be the ancestral allele of PANX1. Q5H is also the more representative allele 
at this locus within human populations and should be included in future studies of PANX1.   
2.6 Experimental Procedures 
Cell culture  
Normal Rat Kidney (NRK) cells (ATCC® CRL-6509™), human triple-negative breast 
cancer Hs578T (ATCC® HTB-126™) and human melanoma A375P (ATCC® CRL-
3224™), A375-MA2 (ATCC® CRL-3223™), human melanoma 131/4-5B1(53) and 
human glioblastoma U87MG (ATCC® HTB-14™) cells were cultured in Dulbecco’s 
Modified Eagle Medium 1X (DMEM 1X; ThermoFisher) containing 4.5 g/L D-glucose, 
L-glutamine, 110 mg/L sodium pyruvate, 10,000 units of penicillin, 10 mg/mL 
streptomycin, and 10% FBS (Wisent Institute). All cells were incubated at 37°C and 5% 
CO2.  Cellular dissociation from culture plates was done using trypsin (0.25%, 1mM 
EDTA 1X; Thermofisher).  
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Generation of CRISPR/Cas9 Knockout cells  
PANX1 knockout cells were generated by CRISPR/Cas9 D10A as described in (54). 
Briefly, cells were transfected with 1 ug each of pSpCas9n(BB)-2A-Puro (PX462) V2.0 
and pSpCas9n(BB)-2A-GFP (PX461) (addgene.org) containing guide RNA sequences for 
human PANX1 in a 6-well plate. PANX1 gRNAs were designed with http://tools.genome-
engineering.org (sequences GTTCTCGGATTTCTTGCTGA and 
CTCCGTGGCCAGTTGAGCGA). 24 hours post transfection, cells were selected with 1 
ug/ml Puromycin for 72 hours. Following selection, cells underwent single colony 
selection via serial dilutions and screened for PANX1 levels by Western blot. Plasmids 
were a gift from Feng Zhang (Addgene plasmid #48140 and #62987). 
Plasmids and transfection  
An expression vector encoding for wild-type PANX1 (Q5), pUNO1-hPANX1 was 
purchased from InvivoGen (San Diego, California, United States). PANX1 variant-
encoding expression vectors (Q5H, Y150F, G168E, T176I, H190Y, S239L, and Q264*) 
were generated by Norclone Biotech Industries (London, Ontario, Canada). For all 
experiments (except those noted as 5 μg), cells were transfected with 1μg of expression 
vectors encoding for Q5, Q5H, Y150F, G168E, T176I, H190Y, S239L, and Q264* using 
Lipofectamine 3000 (ThermoFisher) according to manufacturer’s instructions. Cells were 
analyzed for expression and functional analyses 72- and 96-hours post-transfection. 
Hs578T(KO) clones stably overexpressing Q5 or Q5H were generated by blasticidin 
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selection at 15 μg/mL for one week and underwent single-cell colony selection by serial 
dilution.   
Protein Extraction and Immunoblotting 
Protein lysates from cells were extracted using IP buffer (50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 1% NP-40 (Igepal) (Honeywell Fluka, Seelze, Germany), 0.5% sodium 
deoxycholate, 1 mM sodium fluoride, 4 mM sodium orthovanadate and one tablet of 
complete-mini EDTA-free protease inhibitor (Roche, Mannheim, Germany). Protein 
concentration was quantified using the Pierce bicinchoninic acid (BCA) assay (Thermo 
Fisher Scientific). 30 μg of protein lysates were subjected to 10% SDS-PAGE, blocked 
with 3% bovine serum albumin with 0.05% Tween-20 in 1XPBS or 1XTBS and 
immunoblotted with anti-human PANX1 antibody as previously described in (12) (1:1000; 
PANX1 CT-412; 0.35 μg/μL(26)), anti-glyceraldehyde 3-phosphodehydrogenase 
(GAPDH) antibody (1:1000; Millipore Cat# MAB374, RRID: AB_2107445), anti-N-
cadherin antibody (Cat. No. 6101; BD Biosciences). For detection, goat anti-rabbit 
IRDye®-800CW and goat anti-mouse IRDye®-680RD (LI-COR Biosciences, Lincoln, 
NE, USA) were used as secondary antibodies at 1:10,000 dilutions, and imaged using a LI-
COR Odyssey infrared imaging system (LI-COR Biosciences). Western blot quantification 
and analysis was conducted using Image Studio™ Lite (LI-COR Biosciences).  
 
 
67 
 
De-glycosylation  
Whole cell lysate (10 μg) from Hs578T-KO transiently overexpressing EV, Q5, Q5H, or 
Y150F were incubated with either 500 units or 1000 units of EndoH (Cat. No. P0702S; 
New England BioLabs) or 1 unit of PNGase F (Cat. No. P7367; Sigma-Aldrich) at 37°C 
overnight along with remaining kit components according to manufacturer’s protocol.  
Cell-surface biotinylation  
Forty-eight hours post-transfection, 1x106 cells were cultured in 60-mm culture plates for 
another 48 hours. Cells were rinsed twice with ice-cold DPBS containing calcium and 
magnesium and subsequently incubated with 1.5 mg/mL EZ-Link™ Sulfo-NHS-SS-Biotin 
(Thermo Scientific) in DPBS with calcium and magnesium for 30 min on ice upon which 
cells were washed twice with DPBS and subsequently incubated with 100 mM glycine in 
DPBS to quench remaining biotin for 30 min on ice. Protein lysates were collected, and 
biotinylated proteins were pulled down by incubating 250μg total protein for 16h with 50 
µL (50% slurry) NeutrAvidin agarose beads (Thermo Scientific) in a final volume of 250 
µL in DPBS. Beads were centrifuged (x500g, 4°C) and washed three times with lysis buffer 
and resuspended in 2X Laemmli buffer containing 10% β-mercaptoethanol. Beads were 
boiled for 5 min, centrifuged, and supernatant was collected. 10μg of whole cell lysate was 
used as input and 40 μL of bead supernatant was used in immunoblots. Protein expression 
of N-cadherin and GAPDH via immunoblotting was assessed to use as a positive control 
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for biotinylated cell-surface protein and as a negative control for non-biotinylated 
intracellular proteins, respectively.  
Immunofluorescence 
Cells were grown on glass-coverslips and were fixed 72 hours post-transfection using ice-
cold 8:2 methanol:acetone for 15 min at 4°C and blocked with 2% BSA-PBS. Coverslips 
were incubated with anti-human PANX1 antibody (1:500; PANX1 CT-412; 0.35 μg/μL), 
Hoechst  33342 (1:1000), and Alexa Fluor 488 goat anti-rabbit IgG (2 mg/mL, 1:700), and 
mounted using Airvol (Mowiol 4-88; Sigma Aldrich) prior to imaging. 
Immunofluorescence images were obtained using a Zeiss LSM 800 Confocal Microscope 
with a Plan-Apochromat 63x/1.40 Oil DIC objective (Carl Zeiss, Oberkochen, Germany). 
The laser lines used include 405 nm (Hoechst 33342) and 488 nm (Alexa488). 
Dye-uptake  
Forty-eight hours post-transfection, 300,000 cells were plated on each well of a six-well 
plate. 48-hour post-plating, cells were washed twice with 1XDPBS containing Ca2+ and 
Mg2+ and incubated with DMEM serum media containing 1μM YO-PRO-1 (Cat. No. 
Y3603) for fifteen minutes at room temperature. Subsequently, cells were washed twice 
with 1XDPBS containing Ca2+ and Mg2+ and dissociated from cell-culture plate and 
processed for flow-cytometry analysis using BD FACSCelesta™. Amount of intracellular 
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YO-PRO1 dye uptake was assessed using the 488-nm laser and data was analyzed using 
BD FACSDIVA™ software.  
Whole-cell patch clamp recordings from HEK 293T cells  
Whole-cell voltage-clamp recordings were performed at room temperature (20-22 ˚C) 
using an Axon MultiClamp 700A amplifier and Digidata 1322A data acquisition system 
(Molecular Devices, Sunnyvale, CA, USA). Patch electrodes were pulled using a Narishige 
two-stage puller (PP-83; Narishige, Greenvale, NY, USA) from thin-walled borosilicate 
glass (TW150-F3; WPI, Sarasota, FL, USA). Electrodes had a final resistance of 3-5 MΩ 
when filled with intracellular solution (ICS) containing (in mM): 142 cesium gluconate, 10 
HEPES, 2 MgCl2, 8 NaCl, pH 7.2 (adjusted with 1M Cs-OH) and osmolarity between 290 
and 295 mosmol L−1. Standard extracellular solution (ECS) was composed of (in mM): 
140 NaCl, 5.4 KCl, 25 HEPES, 33 glucose, 2 CaCl2, 1 MgCl2, pH of 7.4 (adjusted with 
10N NaOH) and osmolarity between 300 and 305 mosmol L−1. A computer-controlled, 
multibarrelled perfusion system (SF-77B; Warner Institute, Hamden, CT, USA) was used 
to exchange bath solutions from standard ECS to 100 µM carbenoxolone in ECS (Panx1 
blocker). Transfected cells (identified by presence of mCherry marker) were voltage-
clamped at -60 mV and Panx1 currents were recorded by the application of voltage-ramps 
(±100 mV, 500 ms) to the membrane every 10 seconds. Current–voltage (I–V) 
relationships were constructed from these recordings. Currents were filtered at 2 kHz and 
sampled at 10 kHz, digitized, and acquired using pCLAMP 9.2 software (Molecular 
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Devices). Data was collected from minimum 3 independent experiments and analysed 
using Clampfit 10.7 software (Molecular Devices). 
Cell Growth Assay 
Fifteen thousand cells were plated in a well of a 6-well culture plate at day 0. From day 2 
– day 4 after cell plating, cells were dissociated with Trypsin (0.25%, 1mM EDTA 1X; 
Life Technologies), and number of trypan blue-excluded live cells were counted with an 
automated cell counter Cell Countess II (Thermofisher) as described previously(12).  
Migration Assay 
Twenty thousand cells were plated in each well coated with 0.01% poly-L-lysine (Millipore 
Sigma, Burlington, MA, USA) of a 96-well culture plate and grown to confluence. A 
scratch wound was inflicted with a P200 pipette tip and serum DMEM was replaced with 
serum-free DMEM. Pictures were taken with a brightfield microscope within an hour of 
scratch and at fifteen hours after scratch. Area of migration was quantified with ImageJ 
software.  
Immunoprecipitation and Silver Staining  
Protein lysates were collected 96 hours post-transfection from Hs578T(KO) cells 
transfected with EV, Q5, Q5H, or Y150F upon which confluency was reached. 1 mg of 
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whole cell protein lysate was incubated overnight at 4°C with Protein A/G beads that were 
cleaned twice with 1XDPBS (ThermoFisher) along with 10 μg of anti-human PANX1 
antibody (PANX1 CT-412) crosslinked to Pierce Protein A/G-Agarose beads (Thermo 
Scientific). Subsequently, bound proteins underwent four washes with 500μL of IP buffer. 
Beads were collected and resuspended in 2X Laemmli buffer with 10% β-mercaptoethanol, 
boiled for 5 min, and supernatant were collected after spinning down. Supernatant then was 
subjected to 10% SDS-PAGE and gel was stained with Pierce™ Silver Stain Kit 
(ThermoFisher Scientific) according to manufacturer’s protocol.  
Peptide Identification Using Mass Spectrometry 
The peptides were resuspended in 0.1% formic acid/99.9% water and loaded onto an 
ACQUITY UPLC Symmetry C18 NanoAcquity, 10K, 2G V/M, 180μm x 20mm, 100A, 
5um trapping column (Waters Corporation, Milford, MA) via a Waters NanoAcquity 
UPLC, at a flow rate of 10 uL/min for 6 minutes using 99% buffer A (0.1% formic acid) 
and 1% buffer B (Acetonitrile + 0.1% formic acid).  After trapping the peptides were eluted 
onto the analytical column for separation, using a 95 min run time. Flow was established 
at 300 nL/min for the ACQUITY UPLC Peptide BEH C18 nanoAcquity Column 10K psi, 
130Am 1.7um x 25mm which was held at 35 deg C. The gradient initial condition was 5% 
buffer B. Buffer B then increased to 40% over 60 min, then to 95% over 15 min, then to 
5% over 2min, and finally held at 5% for 13 min for re-equilibration to the initial condition. 
The LC system was directly connected to a NanoFlex (Thermo Electron Corp., Waltham, 
MA) nanospray ionization source with a source voltage of 2.4 KV and was interfaced to 
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an Orbitrap Elite, VelosPro mass spectrometer. The mass spectrometer was controlled by 
Xcalibur software (Thermo, v. 2.7.0) and operated in the data-dependent mode using an 
FT/IT/CID Top 20 scheme.  The MS scan recorded the mass-to-charge ratios (m/z) of ions 
over the range of 400–1450 in FT (resolution of 120000 at m/z 400), positive ion, profile, 
full MS mode using a lock mass (445.120025 m/z). The 20 most abundant multiply charged 
ions were automatically selected for subsequent collisional induced dissociation in ion trap 
mode (IT/CID) with an isolation width of 2.00 Da, rapid scan rate, centroid mode, with 
charge state filtering allowing only ions of +2, +3, and +4 charged states.  Normalized 
Collision energy was 35, and precursor ions were then excluded from further CID for 30 s. 
Bioinformatics 
Allele and genotype frequencies in addition to population genetic distribution information 
for single nucleotide polymorphism rs1138800 encoding for Q5H was extracted from 
Ensembl and ExAC databases. BAM files for colorectal cancer genome sequencing dataset 
from SRA Study Accession No. PRJNA246431 and from WGS files for TCGA SKCM 
cohort were converted to SAM and accessed for A/T/C/G allele counts at chromosome 
position 11:93862493 (GRCh38.p12) using Perl Script. Clinical attributes for TCGA 
SKCM cohort was downloaded from cBioPortal database (36,37). The results for TCGA 
SKCM cohort shown in this investigation are in whole based upon data generated by the 
TCGA Research Network: https://www.cancer.gov/tcga. 
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Q5 and Q5H genome sequencing of cancer cell lines  
Genomic DNA was extracted from cancer cell lines (A375-MA2, U87MG, BeWo, & 
131/4-5B1) using PureLink™ Genomic DNA Mini Kit (Cat. No. K182001; ThermoFisher) 
according to manufacturer’s instructions. Genomic DNA was converted to cDNA using 
High-Capacity cDNA Reverse Transcription Kit (Cat. No. 4368813; ThermoFisher) and 
primers spanning the N-terminus of PANX1 (Forward: 5’-GGAAGCGCTTTGTTCCGC-
3’, Reverse: 5’-CCTCCCACAAACTTTGCCCTA-3’). cDNA products were sent for DNA 
sequencing at the Robarts Research Institute DNA Sequencing Facility (London, Ontario, 
Canada). 
Statistical analyses 
Statistical analyses were performed using GraphPad Prism software (version 8.0; San 
Diego, CA). Data error bars indicate mean ± standard error mean.  
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Supplementary Figure 2.1: A. Genome sequencing for Q5 and Q5H of various cancer 
cell lines. B. Brief clinical summaries of PANX1 somatic mutations derived from 
melanoma patients obtained from cBioPortal database. 
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Supplementary Figure 2.2: Moderate Y150F overexpression allows for cell-surface 
localization but is prevented upon higher overexpression in NRK cells which also 
results in lower cell viability. A. Y150F preserves the ability to traffic to the cell-surface 
upon moderate ectopic expression (1ug of DNA) but is retained intracellularly upon 
overexpression (5ug of DNA) in NRK cells. Green = PANX1, blue = nuclei. Bar = 10 μm. 
B. Both moderate and overexpression of Y150F in NRK result in predominantly Gly-0 and 
Gly-1 species with minimal Gly-2 species relative to wildtype. C. Greater overexpression 
of Y150F significantly reduced number of live cell counts in NRK relative to EV- and Q5-
transfected cells (One-way ANOVA; N=3, n=3; * p < 0.05, ** p < 0.01). 
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Supplementary Figure 2.3: Post-translational modifications of PANX1 detected via 
electrospray-ionization mass-spectrometry in Hs578T(KO) cells transiently 
overexpressing Q5, Q5H, or Y150F. 
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Chapter 3 
3 Discussion and Conclusions 
3.1 Overall Study Conclusions  
The overall objective of this study was to provide a further understanding of various 
domains of the PANX1 polypeptide by introducing naturally occurring PANX1 variants 
and evaluating their effects. By exploring seven PANX1 variants reported in tumours of 
melanoma patients and in human melanoma cell lines, we interrogated three domains of 
the protein implicated in glycosylation and channel function. From this study, we 
uncovered a novel tyrosine phosphorylation site, Y150, that may also regulate complex 
glycosylation of the channel and consequently its cell-surface trafficking. Disruption of 
this phosphorylation site by mutagenesis led to a differentially glycosylated protein with a 
greater capacity to traffic to the cell surface. This finding broadens the novel area of 
PANX1 phosphorylation in that phosphorylation of the channel does not only impact cell-
surface-associated channel activity via interacting proteins but also other aspects that can 
begin prior to reaching the cell-surface. Y150F is not the first reported amino acid 
substitution that does not target the glycosylation site N254 but still affect the glycosylation 
profile of PANX1. Previous studies have demonstrated various PANX1 mutants in separate 
domains that prevent complete development of Gly2 species, similar to Y150F (1-4), thus 
demonstrating that different domains contribute to the delivery of complex glycosylation. 
Lastly, while we were not able to clearly delineate the spatiotemporal onset of Y150 
phosphorylation, we deduce that Y150 phosphorylation may occur at the transition 
between high-mannose and complex glycosylation. This is because of the partial resistance 
to the high-mannose deglycosylation enzyme EndoH that Y150F acquires and due to the 
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detection of Y150 phosphorylation in only Gly2 species (Fig. 3.1). Furthermore, since 
phosphorylated and non-phosphorylated Y150 was detected in the Gly2 state, this suggests 
that Y150 phosphorylation may be lost either at the Golgi or the cell-surface where Gly2 
has been previously demonstrated to localize at (2,5-7), however this requires further 
investigation.  
 
Figure 3.1: Potential spatiotemporal onset and termination pathway of Y150 
phosphorylation of PANX1. PANX1 may receive Y150 phosphorylation at the Gly-2 
state within the Golgi prior to trafficking to the cell-surface upon which loss of Y150 
phosphorylation may occur at the Golgi or at the cell-surface.  
Furthermore, we uncovered an ancestral PANX1 variant, Q5H, mistakenly identified as a 
single-nucleotide polymorphism in various nucleotide and protein sequencing databases. 
What led our interest to this variant was its presence in various human melanoma cell lines 
and other cancer cell lines. It was also classified as a somatic mutation in a minority of 
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tumours of cancer patients in cBioPortal and ICGC databases. Combined with a previous 
finding demonstrating that ectopic expression of Q5H in Chinese Hamster Ovary cells led 
to greater ATP release than Q5, this piqued our interest to develop a proposal in which 
Q5H may be associated with cancer properties, in particular with cancers where PANX1 
has been reported to promote their tumorigenic properties such as breast and melanoma 
cancers. As a result, we generated stable clones of the triple-negative breast cancer 
Hs578T(KO) cells expressing Q5 or Q5H and assessed basic readouts of changes to 
migration and cell growth. In this cellular context, we did not see any changes in channel 
activity, migration, and cell growth. We also assessed if the allele frequency of Q5H was 
associated with clinical attributes of colorectal and melanoma patients. As was seen at the 
cellular level, possessing Q5H did not affect an individual’s risk to developing colorectal 
or melanoma cancers nor did it affect the severity of melanoma cancer. However, we did 
observe that Q5H has a greater allele frequency than Q5 in melanoma and colorectal cancer 
cohorts but was not associated with increased cancer risk. We then found out that this 
variant should be classified as the ancestral allele, and it was also found to be more 
prevalent than the derived allele, Q5, in both global and cancer cohorts. This has 
implications in the Pannexin community where countless researchers have used the less 
common allele, Q5, in their studies as they believed this to be the best and most 
representative PANX1 sequence. Despite our findings that Q5H does not differ 
significantly in the assessed properties of PANX1, we should be prudent before dismissing 
the role of Q5H in other cellular contexts as it has been previously reported to affect 
channel function in a non-cancer cell line (8). Collectively, this work highlights that 
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studying rare and common PANX1 variants can unveil previously unknown properties of 
the widely expressed protein.  
3.2 Study Limitations  
The first limitation is that the direct effects of Y150F on channel activity was not fully 
elucidated. While there was an increase in dye-uptake relative to Q5 and controls, there 
was also more PANX1 channels at the cell-surface to mediate dye-uptake. To determine 
the direct effects of Y150F on channel function, we resorted to whole-cell patch-clamp 
electrophysiology recordings in HEK293T cells, however, the ectopic expression of Y150F 
in these cells resulted in great amounts of cell death preventing further studies of Y150F in 
this cell line. The reduced cell viability also presents another pressing matter in which the 
dye used for dye uptake, YO-PRO1, is also commonly used for assessing apoptosis. To 
alleviate concerns regarding apoptosis, one can exclude apoptotic cells from flow 
cytometric analysis by including an apoptosis marker such as annexin-V. Therefore, the 
enhanced dye uptake in cells expressing Y150F may be a result of greater amounts of 
PANX1 channels at the cell-surface and/or induction of apoptosis. 
Another limitation is the inadequate comparison of Q5H allele frequencies between cancer 
and global cohorts. While the allele frequencies were found to be comparable, it is 
important to note that different methodologies were used to assess for Q5H allele 
frequencies in our study and ExAC’s. Therefore, our crude comparison of Q5H allele 
frequency may be overlooking potential significant differences between global and cancer 
cohorts. Future work should employ the same method, such as analyzing only SNP 
microarrays for both cohorts, to assess allele frequencies across different cohorts to make 
an established comparison.  
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The patient harboring the Y150F mutation possessed an allele frequency of 0.46 within the 
tumour sample (9,10), thus demonstrating that the patient was heterozygous for Y150F. 
The experiments conducted analyzed only expression of Y150F and not the co-expression 
of Y150F and wildtype PANX1, which would further recapitulate the biological setting 
within the patient. As a result, future experiments should analyze the effects of expressing 
Y150F along with wildtype PANX1 on glycosylation, trafficking, and Y150 
phosphorylation. 
 Furthermore, the full breadth of the effects of Q5H on PANX1 channel function was not 
explored. In this thesis, Y150F was only explored in the basal state while Q5H was studied 
in both basal and voltage-activated states. As mentioned before, Q5H has been previously 
reported to affect channel function in K+-activated states (8) and it has been suggested that 
the N-terminus lines the pore in K+-activated states for PANX1 (11). Therefore, it is 
possible that Q5H may impact channel function in cancer cells in K+-stimulated states, 
which should be explored.  
The last limitation is the control used for the experiments comparing Hs578T(KO) stable 
clones expressing Q5 and Q5H. The control was non-transfected and non-selected 
Hs578T(KO) cells and therefore a comparison between the stable clones and the control is 
not sufficient as the process of transfection and colony-selection may induce cellular 
changes that affect dye-uptake, cell growth, and migration. Future experiments should 
include a control that has undergone transfection and colony selection to avoid this.  
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3.3 Future Directions  
The findings of this study highlight several areas that requires further investigation such as 
exploring the role of PANX1 protonation in cancer and related PANX1 mutational 
signatures in cancer, as well as uncovering previously unreported post-translational 
modifications and their role in modulating cancer properties.  
3.3.1 The Role of Protonation of PANX1 in Cancer  
There is accumulating evidence demonstrating that PANX1 channel function is regulated 
by both extracellular and intracellular pH levels. Cytoplasmic acidification by CO2 
attenuated Panx1 currents in oocytes (12) and similarly, intracellular acidification by 
immersing taste receptor cells and Xenopus oocytes in sodium acetate resulted in reduced 
extracellular ATP and channel currents, respectively. Conversely, cytoplasmic alkalization 
with ammonium chloride and IFN- in airway epithelial cells increased ATP release 
relative to cells exposed to IFN- only (13). In addition, the activity level of Zebrafish 
PANX1 has been previously shown to be pH-dependent, with greater dye-uptake occurring 
as extracellular pH increases (14). Vroman et al. (15) has also shown that local acidification 
of the synaptic cleft between photoreceptors, bipolar cells, and horizontal cells as a result 
of PANX1-mediated ATP release, resulted in reduced PANX1 channel activity. Overall, 
as shown in different PANX1 species, lower intracellular and extracellular pH levels 
resulted in a reduction of PANX1 channel activity while it is enhanced with greater 
intracellular and extracellular pH. The mechanism through which how acidification 
inhibits PANX1 channel function may be through internalization of the channel, however 
this requires further investigation. Currently, there is a report demonstrating that 
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administration of ATP to N2A cells stably-expressing Panx1-EGFP resulted in 
significantly greater internalization relative to administration of the slowly hydrolysable 
analogue ATPγS (16). It is important to note that hydrolysis of ATP not only releases the 
different subunits of ATP, but also protons which may act upon PANX1. Therefore, it is 
possible that these effects we see with altering pH may be affecting PANX1 channel 
activity by inducing internalization of the channel. A developing rationale for PANX1 to 
acquire pH-sensitivity is a negative-feedback mechanism for PANX1-mediated ATP 
release. In this model, extracellular ATP that may be derived from PANX1-mediated ATP 
release undergoes enzymatic degradation to adenosine and consequently releases protons. 
The released protons can then act upon the side groups of histidine and cysteine residues 
on the channel to reduce channel activity by inducing PANX1 internalization. This field 
requires further investigations to elucidate the mechanisms of how protonation affects 
overall PANX1 channel function.  
Protonation of cytoplasmic residues is dependent on intracellular pH (pHi), whose 
dynamics often act as a signaling mechanism to regulate several cellular processes and is 
dysregulated in several diseases including cancer where pHi is constitutively increased 
(17,18) and neurodegenerative disorders where pHi is constitutively lower (19,20). It has 
been suggested that cancer cells, which possess increased intracellular pH and decreased 
extracellular pH relative to normal cells, exploit the dysregulated pH system by altering 
the structure and function of pH-sensitive proteins (21). With PANX1 as a novel pH-
sensitive function, it remains unknown how PANX1 channel function differs between 
cancer and normal cells with differential extracellular and intracellular pH levels.  
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The field of PANX1 protonation can be further expanded into the roles of PANX1 in 
cancer. There are notable mutational signatures in the Pannexin family in the context of 
protonation which can be further explored in cancer. PANX1, in addition to PANX2 and 
PANX3, possess a noticeable amount of R  H/C/Q somatic mutations, not including 
other missense and nonsense mutations at arginine residues, representing 10.1%, 19.9%, 
and 14.9% of all reported somatic mutations for PANX1, PANX2, and PANX3, 
respectively (9,10). These types of mutations have been found to be dominant in driver 
mutations relative to passenger mutations (22)(23)(22) and a physiological implication, 
specifically for R  H mutations, has been shown to enhance pH sensing in mutated 
proteins (23). The latter study demonstrated epidermal growth factor receptor EGFR and 
tumor suppressor p53 harbouring an R  H mutation exhibited greater or lower 
tumorigenic effects when intracellular pH was raised or lowered, respectively, relative to 
wildtype. The biochemical significance of R  H mutations is the gain of titrable behavior 
within physiological pH from Histidine as its imidazole ring possesses a pKa of 6.5. This 
finding demonstrated that certain somatic mutations may provide an advantage for cancer 
cells that typically have higher intracellular pH. As of now, there has only been one R  
H PANX1 mutation studied, R217H, which resulted in a loss-of-function mutant in 
HEK293T cells (24). Surprisingly, R217H is also reported in two patients diagnosed with 
prostate adenocarcinoma and glioblastoma multiforme cancers. As aforementioned, there 
is increasing evidence that PANX1 channel function is regulated by both intracellular and 
extracellular pH levels that may be mediated by specific residues that confer pH sensing to 
the protein. In cancer, somatic mutations such as R  H may provide a gain in pH sensing 
for PANX1 and possibly providing a fitness advantage for cancer cells harboring such 
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mutations. Future studies can focus on the role of protonation on PANX1 channel function 
and the fitness advantages certain RH/C/Q mutations of PANX1 may confer to cancer 
cells.  
3.3.2 Potential PTMs of PANX1 
Our study’s mass spectrometry results have unveiled previously unidentified post-
translational modifications (Suppl. Fig. 2.3) that may play key roles in various aspects of 
PANX1 as described below.   
As of now, only three tyrosine phosphorylation sites of PANX1 (Y150, Y198 and Y308) 
have been experimentally established, along with a report strongly suggesting that S206 is 
a serine phosphorylation site. Our results demonstrate that PANX1 in Hs578T(KO) cells 
also undergo phosphorylation at the following residues between Q5, Q5H, and Y150F as 
indicated: S159 (Y150F), S137 (Y150F), Y309 (Q5), Y150(Q5 & Q5H), T382 (Q5), T368 
(Q5), S357 (Q5), T396 (Q5), S344 (Q5H), and S159 (Q5) (Suppl. Fig. 2.3). As discussed 
in Chapter 1.5.2, phosphorylation has been shown to play key roles in regulating channel 
function and it remains unknown how phosphorylation at the indicated sites affect channel 
function. Therefore, it would be of great interest to analyze how mutagenesis of these sites 
affect glycosylation, trafficking, and channel-function.  
3.3.2.1 N-terminal methionine cleavage and acetylation  
While rarely occurring in prokaryotes, the co-translational process of initial methionine 
cleavage and N-terminus acetylation is one of the most common PTMs occurring in 
eukaryotic cells. N-terminal acetylation is the covalent addition of an acetyl group to the 
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free α-amino group at the N-terminus. Due to the lack of N-terminal deacetylases 
discovered, it is believed that N-terminal acetylation is an irreversible process (25). 
Nonetheless, N-terminal acetylation has been demonstrated to impact the acetylated 
protein in different ways depending on the substrate and its cellular context.  N-terminal 
acetylation has been shown to influence protein stability by targeting proteins for 
polyubiquitination and proteasomal degradation (26), protein folding by acting as protein 
quality control (27-30), formation of protein complexes by altering charge and increasing 
hydrophobicity (31-33), as well as targeting proteins to the membrane through interacting 
with protein-protein interactions or through increasing the substrate’s affinity for 
moderately charged vesicles (34-36). As of now, there has only been one report of an ion 
channel experiencing N-terminal methionine cleavage and acetylation (37).  
PANX1 is predicted to undergo these two co-translational processes as analyzed by 
Terminus (v0.4.1) (38), and mass spectrometry results from our lab demonstrate that 
PANX1 does experience these two PTMs, but their impact remains unknown on overall 
PANX1 function.  
3.4 Summary 
In conclusion, from studying seven naturally occurring PANX1 variants, we have 
uncovered two that have deeper implications in our understanding of PANX1 and are 
significant contributions to the pannexin research field. The variant Y150F produced a 
hypo-glycosylated channel that lacked phosphorylation of Y150 but possessed a greater 
capacity to traffic to the cell-surface. We also identified an ancestral variant, Q5H, that is 
the more representative allele at this locus in global and cancer cohorts but was not 
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associated with risk to colorectal and melanoma cancers. Q5H also did not differ from Q5 
in glycosylation, cell-surface localization, and channel activity in breast cancer cells, 
although it has been previously demonstrated to confer a gain in channel activity in normal 
cells. Overall, these findings open up a new area of research in the role of phosphorylation 
beyond channel activity and the expansion of the study of Q5H into other diseases.  
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